Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Immunology | Hematology
Disease Category: Non-Hodgkin's Lymphoma
Location: United States, WV

Clinical Trial Details

Overview

Research Study Summary

MEDI-551-1088 - A Phase 2 Randomized Open-Label Study of MEDI-551 in Adults with Relapsed or Refractory Diffused Large B-Cell Lymphoma

Purpose

Objective - overall response rate, including partial response and complete responsem of subjects trated with MEDI-551 when used in combination with a chemotherapy regimen containing either ifosfamide, carboplatin, and etoposide (ICE) or dexamethasone cytarabine, and cisplatin (DHAP) versus rituximab in combination with ICE or DHAP in subjects with relapsed or refractory diffuse large B-cell lymphoma

Patient Inclusion Criteria: See www.hsc.wvu.edu/mbrcc/ctru/ for additional information.

Patient Exclusion Criteria: See www.hsc.wvu.edu/mbrcc/ctru/ for additional information.

To Learn more
Phase

2

Gender

Both Male and Female

Age

N/A

Overall Status

Recruiting

Facility Type

N/A

Contact

West Virginia University - Clinical Trials Research Unit
PO Box 9260
Morgantown, WV 26506
Phone: 304-293-7374

View Map

CW ID: 183172

Date Last Changed: July 17, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.